India markets close in 1 hour 24 minutes
  • BSE SENSEX

    48,009.58
    -71.09 (-0.15%)
     
  • Nifty 50

    14,380.05
    -26.10 (-0.18%)
     
  • USD/INR

    74.9710
    -0.1390 (-0.19%)
     
  • Dow

    33,815.90
    -321.41 (-0.94%)
     
  • Nasdaq

    13,818.41
    -131.81 (-0.94%)
     
  • BTC-INR

    3,642,425.75
    -433,319.25 (-10.63%)
     
  • CMC Crypto 200

    1,104.46
    -138.60 (-11.15%)
     
  • Hang Seng

    29,078.75
    +323.41 (+1.12%)
     
  • Nikkei

    29,020.63
    -167.54 (-0.57%)
     
  • EUR/INR

    90.3777
    +0.1031 (+0.11%)
     
  • GBP/INR

    103.9437
    +0.0069 (+0.01%)
     
  • AED/INR

    20.3540
    -0.0510 (-0.25%)
     
  • INR/JPY

    1.4363
    +0.0017 (+0.12%)
     
  • SGD/INR

    56.4870
    -0.0450 (-0.08%)
     

Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences

·2-min read

Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will participate in two upcoming investor conferences:

  • Cowen 41st Annual Health Care Conference on Tuesday, March 2, 2021. Management will participate in a Microbiome panel discussion as well as 1x1 meetings.

  • Chardan 3rd Annual Microbiome Medicines Summit on Monday, March 8, 2021. Management will present a corporate overview at 2:30 p.m. ET and participate in 1x1 meetings.

An audio webcast of the Chardan Summit presentation will be available under the "Investors and Media" section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210226005085/en/

Contacts

PR Contact
Kristin Ainsworth
kainsworth@serestherapeutics.com

IR Contact
Carlo Tanzi, Ph.D.
ctanzi@serestherapeutics.com